4,901 trials
Hepatitis C, Chronic
Primary: Feasibility of Peginterferon Alfa-2a Administration by Autoinjector — 11; 14; 49; 45 participants
Hodgkin Lymphoma · Anaplastic Large-cell Lymphoma
Primary: Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, Predose — NA; NA; NA; NA ng/mL
Schizophrenia
Primary: Blood Levels of Drug — 1.5 ng/ml
Schizophrenia
Primary: Change in Percentage Dopamine D2/D3 Receptor Occupancy — 36; 59; 2; 13 percentage occupancy
Irritation/Irritant
Primary: Cumulative Irritation Score of RUT058-60 Hypochlorous Acid Solution (106 mg/L) on Healthy Human Skin — 1.00; 2.46; 1.34; 0.58 units on a scale
Hepatitis C
Primary: Mean Change From Baseline in HCV Viral Load — -0.42; -1.88; -3.39 Log10 change
Healthy Subjects
Primary: Description of the Safety Profile in Terms of Adverse Events (AE),Vital Signs, ECG, Lab Variables, Immunogenicity and Physical Examination — 2; 3; 2; 1 Participants
Major Depressive Disorder
Primary: Number of Participants Who Tolerated Brexpiprazole — 6; 7; 5 participants
Cancer · Brain Tumors
Primary: Area Under the Receiver Operating Curve (ROC AUC) Values for PET Imaging Techniques — 0.98; 0.91; 0.89; 0.82 Probability
Hypertension
Primary: Percentage of Participants With a Clinical or Laboratory Adverse Experience — 33.3; 53.8; 41.7; 61.5 Percentage of participants
Hepatic Insufficiency
Primary: AUC (0-inf) of Nintedanib — 200; 674; 92.7; 77.8 ng*h/mL
Neoplasms, Cystic, Mucinous, and Serous
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 7; 16 participants
Hyperlipidemia · Mixed Dyslipidemia
Primary: Maximum Observed Serum Concentration (Cmax) of Evolocumab — 21.3; 15.1; 11.7 μg/mL
Renal Impairment · Renal Insufficiency · Kidney Disease
Primary: AUC — 102.0; 168.9; 107.4; 188.5 h*ng/mL
Sleep Initiation and Maintenance Disorders
Primary: Wake After Sleep Onset (WASO) With LY2624803 Compared to Placebo — 58.88; 40.70; 32.27; 18.42 minutes (min) — p=0.908